Vitranu

Traditional injections lead to fluctuating drug concentrations—spiking above therapeutic levels and then dropping below effectiveness. Vitranu’s technology changes that. Our injectable, dissolvable microcapsule is engineered to maintain consistent, controlled drug release above the therapeutic threshold. This breakthrough in drug delivery is designed and tested for monoclonal antibodies and genetic medicines, paving the way for more durable, predictable treatment outcomes. Innovating for precision. Delivering for patients.

Vitranu is proud to sponsor the 5th Annual WET AMD & Diabetic Eye Disease Summit in Boston, March 18-20. As we continue to push the boundaries of ophthalmic drug delivery, we are committed to advancing the shift from systemic treatments to localized, episodic therapies. Our revolutionary microcapsule technology is designed to improve treatment efficacy, patient adherence, and overall outcomes. Looking forward to engaging with industry leaders and innovators at this important event.

https://lnkd.in/gBWAquNr

The Vitranu injectable microcapsule delivers a breakthrough in ophthalmology, achieving 9 months of sustained release of a market-leading wet macular degeneration drug, active bevacizumab. This platform combines excellent safety with adjustable drug delivery, offering a transformative solution for patients and providers by significantly reducing the treatment burden. This innovation reinforces Vitranu’s commitment to advancing ophthalmic drug delivery technologies and addressing critical unmet needs in the field.

Vitranu technology has a unique ability to hold a reservoir of the active pharmaceutical and sustain delivery till depleted. A breakthrough in the potential consistency of therapy delivered.

Our CEO John Black will now be in attendance. Please reach out via the partnering tool to connect at PODD conference next week.

For Immediate Release October 2024 John Black Appointed as CEO of Vitranu, Inc. Vitranu, Inc. is pleased to announce the appointment of John Black as Chief Executive Officer. Black will succeed Gordon in the role, bringing nearly 20 years of leadership experience across the medical industry. He has held senior positions in both startups and established organizations, demonstrating expertise in strategy, sales, and product commercialization. With a robust background in allied health and business, Black has built a track record of successfully launching new technologies, securing regulatory clearances, and developing innovative sales strategies. He has extensive experience with biomaterials, biologics, and AI-based imaging solutions, as well as building hybrid direct and distribution sales models. In his new role, Black will focus on delivering Vitranu’s game-changing nanotechnology to patients in need of extended delivery solutions. His leadership will be pivotal in securing strategic partnerships, advancing the company through key regulatory milestones, and driving sustainable growth within the ophthalmology market.

Sight is our most precious sense, and losing it is debilitating. At Vitranu, we're working to solve the problem of injection burden in the treatment of eye disease, by developing a unique drug delivery platform to deliver many months' worth of treatment in a single injection. Vitranu CEO Gordon Bethwaite shares some insight into our progress and goals in this video. If you share our passion for preserving vision, we'd love to hear from you. #maculardegeneration #ophthalmology #optometry #vision #drugdelivery